Future and Innovation
iCHOR is expanding its platform with additional sizes, indications, and design enhancements to address a broader range of vascular conditions.
Yes. iCHOR is actively developing solutions tailored for dialysis access maintenance and intervention.
General market issues
Peripheral arterial disease, deep vein thrombosis, limb ischemia, and other clot-related occlusions are major unmet needs.
It can reduce procedural trauma, shorten recovery, and expand treatment options for patients who may not be ideal surgical candidates.
Patients with PAD, venous thrombosis, limb ischemia, and other obstructive vascular disease are key target groups.
It is a large, underserved segment with strong clinical demand and growing interest in less invasive treatment methods.
It can worsen circulation, raise the risk of limb loss, and lead to major quality-of-life and mobility issues.
Market economics
Reimbursement strongly influences whether hospitals and clinicians can widely adopt a particular vascular technology.
Medicare is making ASCs and OBLs more viable for thrombectomy mainly by expanding what can be done in these settings and by improving payment for a wider set of procedures and related devices. In 2026, CMS finalized a 2.6% average ASC update and added 302 procedures to the ASC Covered Procedures List, which broadens the menu of cases that can be moved out of the hospital.
For thrombectomy, the practical effect is that more clot-removal cases can be scheduled where they are operationally and financially easier to perform, especially in ASCs and office-based labs. Medicare policy has increasingly recognized that many outpatient vascular procedures can be done safely outside the hospital, which supports the shift.
They help hospitals assess clinical benefit, workflow fit, and economic value before approving new devices.
Clear clinical benefit, strong economics, and a broad enough addressable market to support adoption and growth.
Underserved areas often have high unmet need, less direct competition, and stronger room for adoption.
The U.S. market is often shaped by reimbursement and hospital adoption, while international growth can be driven by scale and broader access needs.
Future opportunities
Pulmonary embolism, dialysis graft and fistula clots, and internal jugular or radial access applications are logical adjacent markets.
It is a large, underserved area where clot management is a frequent and costly problem.
PE represents a serious clot burden where minimally invasive treatment options could have major clinical impact.
A platform can support expansion into multiple clot-related indications without rebuilding the core technology from scratch.
It helps validate usability, performance, pricing, and market fit before broad commercialization.
Buying and adoption
Evidence of safety, effectiveness, workflow simplicity, and confidence that the device will solve a real clinical problem.
Consistency helps reduce variability across operators and can make outcomes more predictable.
They usually look for a balance: strong clinical value without adding unnecessary procedural cost or complexity.
Common barriers include proof of value, reimbursement uncertainty, training burden, and competition from established approaches.
Better clot removal with less invasiveness, better safety, and improved outcomes for patients who need faster restoration of blood flow.
